News
-
-
PRESS RELEASE
Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed
Curatis Holding AG announces completion of business combination with Curatis AG, trading on SIX Swiss Exchange under CURN.SW. Specializes in orphan drugs with risk-balanced model -
-
PRESS RELEASE
Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split
Kinarus Therapeutics Holding AG releases FY2023 Financial Statements & details on Business Combination with Curatis AG and Reverse Share Split. Postponement of 2023 Annual Report. Reverse Share Split to be implemented on 25 April 2024 -
-
PRESS RELEASE
Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis
Kinarus Therapeutics Holding AG shareholders approve resolutions for Business Combination with Curatis at Extraordinary General Meeting. Transaction closing expected by end of April 2024 -
-
PRESS RELEASE
Publication of unaudited financial statements of Kinarus Therapeutics Holding AG (only) for FY2023
Kinarus Therapeutics Holding AG releases unaudited financial statements for FY2023 in advance of extraordinary general meeting regarding Business Combination with Curatis AG. Implementation ongoing with expected closing in April 2024 -
PRESS RELEASE
Courts of Basel-Stadt have revoked bankruptcy of Kinarus Therapeutics Holding AG
Courts of Basel-Stadt have revoked the bankruptcy of Kinarus Therapeutics Holding AG, a SIX Swiss Exchange listed therapeutic drug development company. The revocation is a condition for the business combination with Curatis AG -
PRESS RELEASE
Kinarus Therapeutics Holding AG in Liquidation and Curatis AG propose to combine companies and reverse bankruptcy procedures of Kinarus Therapeutics Holding AG in Liquidation
Kinarus Therapeutics Holding AG in Liquidation and Curatis AG propose a Combination Transaction to reverse bankruptcy procedures, with conditions and a financing transaction. The combined entity will focus on drug development for speciality medicines. The planned transaction is subject to various approvals and closing conditions
-
Southern Energy Corp. Announces Amendments to Outstanding Convertible Debentures
-
TEAM JOOPITER Collection Will Be Officially Launched on June 18
-
The Juneteenth Foundation is Back With Its 4th Annual Juneteenth Honors Festival in Washington, DC, Continuing the Movement to Make Juneteenth a Staple Holiday Across America
-
BRIXY’s New Shampoo Bars Lather on the Benefits: Hydrating and Strengthening Formulations That Help Preserve Hair and the Planet
-
Ascendant Resources Announces Results of Annual General Meeting of Shareholders
-
Cantourage Group SE records highest monthly revenue in company history in May 2024
-
Cairn Homes Plc: Transaction in Own Shares
-
Wacker Neuson Group opens new distribution center in Mülheim-Kärlich
-
ATOSS Software SE: Completion of stock split
-
Marinomed Biotech AG secures licensure with leading Consumer Health Care player for the distribution of Carragelose® products in Europe
-
Europorte and Kerlink revolutionize freight by launching Track Value, the first logistics application using Kinéis IoT space connectivity
-
AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2024
-
Declaration of voting rights at the end of May 2024
-
The Board of Directors renews Iris Knobloch as Chair of the Board of Directors
-
CDA - Acquisition of 86,5% of Urban Group